Oxidative Stress in Women Treated With Atosiban for Impending Preterm Birth

Overview

Oxidative stress is recognized as a important factor in the pathogenesis premature birth. Preterm birth is defined as delivery before 37 completed weeks of gestation and it is the leading cause of neonatal morbidity and mortality. The investigators conducted this analysis to investigate the safety of administration of Atosiban – a reversible, competitive antagonist of the oxytocin receptor in the treatment of preterm labor and its impact on the level of oxidative stress after 48 hours of tocolytic treatment.

Full Title of Study: “Evaluation of Oxidative and Antioxidative Status of Pregnant Women Suffering From Threatened Preterm Birth During Tocolytic Treatment With Atosiban”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: N/A
    • Intervention Model: Single Group Assignment
    • Primary Purpose: Treatment
    • Masking: None (Open Label)
  • Study Primary Completion Date: June 10, 2018

Detailed Description

Atosiban (1-(3-mercaptopropanoic acid)-2-(O-ethyl-D-tyrosine)-4-L-threonine-8-L-ornithine-oxytocin) is licensed for clinical use in women suffering from threatened premature birth and is widely used in clinical practice in Europe because of its low side effect profile. The impact of Atosiban on pregnancy outcomes in women has been investigated in recent years and the research has shown its ability to reduce intracytoplasmic calcium release and downregulate prostaglandin synthesis as oxytocin receptor antagonist. While a role of Atosiban in the modulation of myometrial contractility is well-described, its effect on many other functions is not so well known. The serum and plasma samples take for the measurement of total oxidant status (TOS), total antioxidant status (TAS), level of 3-nitrotyrosine (3-NT), and carbonyl and thiol groups will be stored at -70°C in aliquots for subsequent biochemical analysis and processed within two months.

Interventions

  • Drug: Atosiban
    • The initial dose of Atosiban (Tractocile, Ferring Pharmaceuticals A/S, Copenhagen, Denmark) will be give as a single intravenous bolus dose (6.75 mg in 0.9 ml isotonic sodium chloride solution). This will be follow immediately by intravenous infusion of 300 μg/min of Atosiban in 5% glucose for 3 hours, and then 100 μg/min for up to 48 hours. Venous blood samples from a forearm vein will take before and after 48 hours of continuous administration tocolytic therapy with Atosiban.

Arms, Groups and Cohorts

  • Other: Atosiban
    • Total oxidant status (TOS), total antioxidant status (TAS) and oxidative stress index (OSI) values as well as 3-nitrotyrosine, carbonyl and thiol groups levels weill be measure using ELISA test in serum and plasma of 64 pregnant women before and after 48 hours of continuous administration of Atosiban.

Clinical Trial Outcome Measures

Primary Measures

  • Delay preterm delivery for 48 hours
    • Time Frame: 48 hours
    • Delay preterm delivery for 48 hours, thus allowing administration of corticosteroids to induce surfactant production in fetal lungs and improve neonatal outcome

Secondary Measures

  • Apgar score
    • Time Frame: At birth
    • Apgar score
  • Weight
    • Time Frame: At birth
    • Weight
  • Incidence of duration of hospitalization
    • Time Frame: Up to 28 days after birth
    • Incidence of duration of hospitalization
  • Time to delivery measured from start of Atosiban administration
    • Time Frame: Up to 15 weeks from start of Atosiban administration
    • Time to delivery measured from start of Atosiban administration

Participating in This Clinical Trial

Inclusion Criteria

  • pregnant women between 24-35 weeks' gestation receiving prenatal care due to the risk of premature birth – intact membranes – evidence of premature labor (regular, painful and persistent uterine contractions; cervical changes) Exclusion Criteria:

  • acute fetal distress – other conditions requiring immediate delivery (eclampsia and severe pre-eclampsia, placenta previa, abruptio placenta) – vaginal bleeding, – premature rupture of membranes – chorioamnionitis, – fetal congenital malformations, – intrauterine growth restriction, – the use of any tocolytic drugs during pregnancy before admission to the hospital – circulatory system diseases (e.g. heart defects, hypertension), – symptoms of infection – other diseases that may increase oxidative stress

Gender Eligibility: Female

Minimum Age: 18 Years

Maximum Age: 45 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Polish Mother Memorial Hospital Research Institute
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Mariusz Grzesiak, Ph.D. MD, Principal Investigator, Department of Obstetrics, Perinatology and Gynecology, Polish Mother’s Memorial Hospital-Research Institute

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.